Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis
- PMID: 35242567
- PMCID: PMC8856920
- DOI: 10.1016/j.ymgmr.2021.100833
Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis
Abstract
Wolman Disease (WD) is a severe multi-system metabolic disease due to lysosomal acid lipase (LAL) deficiency. We report on a WD infant who developed an unusual hemophagocytic lymphohistiocytosis (HLH) phenotype related to WD treated with sebelipase alfa. A male baby came to our attention at six months of life for respiratory insufficiency and sepsis, abdominal distension, severe hepatosplenomegaly, diarrhea, and severe growth retardation. HLH was diagnosed and treated with intravenous immunoglobulin, steroids, cyclosporine, broad-spectrum antimicrobial therapy, and finally with the anti-IL-6 drug tocilizumab. WD was suspected for the presence of adrenal calcifications and it was confirmed by LAL enzyme activity and by molecular analysis of LIPA. Plasma oxysterols cholestan-3β,5α,6β-triol (C-triol), and 7-ketocholesterol (7-KC) were markedly increased. Sebelipase alfa was started with progressive amelioration of biochemical and clinical features. The child died from sepsis, 2 months after sebelipase discontinuation requested by parents. Our case shows the importance of an early diagnosis of WD and confirms the difficulty to reach a diagnosis in the HLH phenotype. Sebelipase alpha is an effective treatment for LAL deficiency, also in children affected by WD. Further data are necessary to confirm the utility of measuring plasma c-triol as a biochemical marker of the disease.
Keywords: Adrenal calcifications; Hemophagocytic lymphohistiocytosis; Lysosomal acid lipase; Oxysterols; Sebelipase alpha; Wolman disease.
© 2021 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa.Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):e77-e82. doi: 10.1016/j.clinre.2018.03.012. Epub 2018 Apr 26. Clin Res Hepatol Gastroenterol. 2018. PMID: 29705274
-
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.Orphanet J Rare Dis. 2021 Jan 6;16(1):13. doi: 10.1186/s13023-020-01577-4. Orphanet J Rare Dis. 2021. PMID: 33407676 Free PMC article.
-
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.Orphanet J Rare Dis. 2017 Feb 8;12(1):25. doi: 10.1186/s13023-017-0587-3. Orphanet J Rare Dis. 2017. PMID: 28179030 Free PMC article. Clinical Trial.
-
Wolman disease presenting with hemophagocytic lymphohistiocytosis syndrome and a novel LIPA gene variant: a case report and review of the literature.J Med Case Rep. 2023 Aug 29;17(1):369. doi: 10.1186/s13256-023-04116-4. J Med Case Rep. 2023. PMID: 37641143 Free PMC article. Review.
-
Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review.Ther Adv Rare Dis. 2021 Jul 18;2:26330040211026928. doi: 10.1177/26330040211026928. eCollection 2021 Jan-Dec. Ther Adv Rare Dis. 2021. PMID: 37181111 Free PMC article. Review.
Cited by
-
Cholesterol crystals in the pathogenesis of atherosclerosis.Nat Rev Cardiol. 2025 May;22(5):315-332. doi: 10.1038/s41569-024-01100-3. Epub 2024 Nov 18. Nat Rev Cardiol. 2025. PMID: 39558130 Review.
-
Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease.Orphanet J Rare Dis. 2024 Jun 25;19(1):244. doi: 10.1186/s13023-024-03219-5. Orphanet J Rare Dis. 2024. PMID: 38918870 Free PMC article.
-
Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis.Nat Rev Cardiol. 2025 Mar;22(3):149-164. doi: 10.1038/s41569-024-01072-4. Epub 2024 Sep 20. Nat Rev Cardiol. 2025. PMID: 39304748 Review.
References
-
- Grabowski G., Charnas L., Du H. 2021. Lysosomal acid lipase deficiencies: the Wolman disease/cholesterol ester storage disease spectrum. The Online Metabolic & Molecular Bases of Inherited Disease. http://www.ommbid.com/OMMBID/a/c.html/lysosomal_disorders/acid_lipase_de....
-
- Tinsa F., Ben Romdhane M., Boudabous H., Bel Hadj I., Brini I., Tebib N., Louati H., Bekri S., Boussetta K. A novel mutation c.153 C>a in a tunisian girl with wolman disease and unusual presentation: hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 2019;41:e193–e196. doi: 10.1097/MPH.0000000000001192. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources